Imvax's IGV-001 Shows 40% Survival Gain in Unmethylated MGMT Glioblastoma Subgroup; FDA Aligns on Phase 3 Design
核心洞察
Imvax reported a prespecified Phase 2b subgroup analysis showing IGV-001 extended median overall survival to 14.8 months versus 10.6 months with placebo in unmethylated MGMT (搜索) newly diagnosed glioblastoma (搜索).
The 4.2-month, 40% survival difference in the 48-patient uMGMT subgroup yielded a hazard ratio of 0.60 with a P value of 0.0808, missing conventional statistical significance.
IGV-001 also delayed Karnofsky Performance Status deterioration and produced favorable quality-of-life measures with lower severe toxicity and serious adverse event burden than placebo.
Imvax, Inc. (搜索) reported additional data from its randomized, multicenter, double-blind, placebo-controlled Phase 2b trial of IGV-001 in 99 patients with newly diagnosed glioblastoma (搜索) (ndGBM), highlighting a prespecified subgroup analysis in patients whose tumors carry an unmethylated O6-methylguanine-DNA methyltransferase promoter (uMGMT). In that subgroup of 48 patients, those treated with IGV-001 achieved a median overall survival (mOS) of 14.8 months versus 10.6 months in the placebo arm — a difference of 4.2 months, or 40% (HR 0.60, P=0.0808).
The company also disclosed that it has secured FDA alignment on key elements of a proposed Phase 3 trial design in uMGMT ndGBM. The abstract reporting the Phase 2b results has been accepted for poster and rapid oral presentation at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), taking place November 12–15, 2026 in Philadelphia.
Functional and Safety Signals Favor IGV-001
Beyond the survival endpoint, Imvax reported that patients in the IGV-001 arm experienced delayed deterioration of Karnofsky Performance Status (KPS) score, favorable quality-of-life measures, lower rates of severe toxicities, and a reduced burden of serious adverse events compared with the placebo arm.
In the overall Phase 2b trial population, patients in the IGV-001 arm had a mOS of 20.3 months, a difference of 6.3 months, or 45%, compared with a mOS of 14.0 months in the placebo arm. Median follow-up for all patients in the study was 22 months. The company stated there were no drug-related serious adverse events in the treatment arm, and that the safety profile observed in the Phase 2b trial is favorable and consistent with that seen in a previous Phase 1b study (n=33).
"Patients with uMGMT ndGBM have an urgent need for more effective treatment options. The magnitude and consistency of the treatment effect observed across survival, functional, and patient-reported outcome measures support continued investigation of IGV-001 in the uMGMT patient population," said J. Bradley Elder, M.D., Director, Neurosurgical Oncology, Professor, Department of Neurological Surgery at The Ohio State University Wexner Medical Center and the highest enrolling investigator in the Phase 2b trial.
A High-Risk Population Without Approved Options
Patients with uMGMT ndGBM account for an estimated 55% to 60% of all ndGBM patients and represent a biologically high-risk cohort with limited therapeutic options and poor expected outcomes under current standard-of-care approaches, according to Imvax.
Glioblastoma (搜索) is the most common aggressive malignant primary brain cancer in adults and has resisted meaningful treatment advances for decades, with approximately 14,000 people diagnosed each year in the United States. Current treatment generally consists of maximal safe resection followed by radiotherapy and temozolomide, with subsequent maintenance temozolomide. MGMT (搜索) promoter methylation is a biomarker associated with benefit from temozolomide; patients whose tumors have an unmethylated MGMT promoter generally derive limited benefit from the agent, experience shorter overall survival than patients with methylated tumors, and currently have no approved treatment specifically for uMGMT disease.
Phase 3 Design and Regulatory Path
The Phase 2b trial (NCT04485949) evaluated the safety and efficacy of IGV-001 in 99 patients with ndGBM across 19 U.S. sites, randomizing participants 2:1 to IGV-001 or placebo and assessing progression-free survival, overall survival, and safety.
Imvax said it met with the FDA earlier this year to discuss the Phase 2b data and the regulatory pathway for IGV-001, followed by a July meeting at which the parties aligned on key elements of a proposed randomized, open-label Phase 3 study in approximately 375 uMGMT ndGBM patients in the United States. The planned primary endpoint is overall survival, and the study would include an interim analysis after a specified number of patient deaths. Imvax has incorporated FDA feedback into the proposed final protocol, which it plans to submit to the agency in the coming months.
"With the FDA's recent feedback, we will be finalizing the protocol for a Phase 3 study focused on patients with uMGMT ndGBM, a population that has lacked meaningful treatment innovation in decades and where we saw a clinically meaningful benefit in the Phase 2b study," said John P. Furey, Executive Chair of the Imvax Board of Directors. "We are also actively pursuing financing to support the initiation of this planned Phase 3 trial in 2027."
Platform and Candidate Status
IGV-001 is an investigational, autologous biologic-device combination product candidate derived from Imvax's proprietary Goldspire (搜索) immuno-oncology platform, which is designed to induce a patient-specific immune response against a broad range of tumor antigens. The FDA has granted IGV-001 Fast Track designation and Orphan Drug Designation for the treatment of ndGBM. IGV-001 has not been approved by the FDA or any other regulatory authority.
Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies through the Goldspire (搜索) platform, with IGV-001 as its lead candidate in newly diagnosed glioblastoma (搜索). The company is headquartered in Philadelphia.
The SNO 2026 abstract, titled "Initial efficacy and safety results of a randomized, double-blind, Phase 2b study to evaluate IGV-001, an autologous cell immunotherapy, plus standard of care (SOC) versus placebo (PBO) plus SOC in adult patients with newly diagnosed glioblastoma (搜索) (ndGBM)," is abstract number CTIM-05 and will be presented at the Pennsylvania Convention Center in Philadelphia.